Morgan Stanley raised the firm’s price target on BioNTech (BNTX) to $140 from $139 and keeps an Overweight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech SE Announces Virtual Annual General Meeting for 2025
- BioNTech SE and University of Pennsylvania Finalize Agreements Amidst Settlement
- Promising Potential of BioNTech’s BNT327 in ES-SCLC Treatment: Analyst’s Insight
- BioNTech price target lowered to $145 from $150 at H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today